June 27, 2024
1 min watch
Save
VIDEO: Regenxbio offers updates on ABBV-RGX-314 programs
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Steve Pakola, MD, chief medical officer of Regenxbio, shares updates on the company’s retina programs.
ABBV-RGX-314 (Regenxbio, AbbVie) “is well through a big chunk of our pivotal program for subretinal delivery for treatment of wet [age-related macular degeneration],” Pakola said. “We’re also excited with the advance of our nonsurgical one-time in-office treatment via the suprachoroidal delivery program, which is evaluating this treatment for wet AMD but also for diabetic retinopathy.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Pakola reports being the chief medical officer of Regenxbio.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.